What is the 13F Pro Quality Score for LRMR?

13F Pro ranks Larimar Therapeutics, Inc. (LRMR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LRMR's current score at https://13fpro.ai/research/LRMR (free sign-up required for the full ranking).

Where does 13F Pro source LRMR data?

All Larimar Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Larimar Therapeutics, Inc. files with the SEC under CIK 1374690. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LRMR in?

Larimar Therapeutics, Inc. (LRMR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LRMR research updated on 13F Pro?

LRMR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Larimar Therapeutics, Inc.(LRMR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1374690 LRMR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

LRMR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Larimar Therapeutics, Inc. (LRMR), a Healthcare sector company. LRMR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Larimar Therapeutics, Inc. reports net income of $-29.6M, free cash flow of $-44.6M. Top institutional holders of LRMR by reported 13-F value include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Blue Owl Capital Holdings, BlackRock,, based on the most recent SEC filings. LRMR trades on the Nasdaq exchange and files with the SEC under CIK 1374690. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LRMR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Larimar Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-29.6M

Free Cash Flow

Q1 2026

$-44.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2023

FY19 $0.00FY20 —FY21 —FY23 —

Net Income

+27.0% YoY

$-36.9MFY 2023

FY19 $-23.1MFY20 $-42.5MFY21 $-50.6MFY23 $-36.9M

Operating Income

+17.3% YoY

$-41.8MFY 2023

FY19 $-23.2MFY20 $-42.8MFY21 $-50.5MFY23 $-41.8M

EPS (Diluted)

+71.5% YoY

$-0.84FY 2023

FY19 —FY20 $-3.57FY21 $-2.95FY23 $-0.84

Total Assets

+22.0% YoY

$95.9MFY 2023

FY19 $5.2MFY20 $104.7MFY21 $78.7MFY23 $95.9M

Total Debt

—FY 2023

FY19 $14.5MFY20 —FY21 —FY23 —

Op. Cash Flow

+20.5% YoY

$-33.5MFY 2023

FY19 $-22.7MFY20 $-42.2MFY21 $-42.1MFY23 $-33.5M

Metric	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	—	—	—	$0.00	$0.00	$0.00
Net Income	$-36.9M +27.0%	$-50.6M -19.2%	$-42.5M -83.7%	$-23.1M +62.3%	$-61.4M -18.0%	$-52.0M
Operating Income	$-41.8M +17.3%	$-50.5M -17.9%	$-42.8M -84.4%	$-23.2M +62.0%	$-61.1M -15.3%	$-53.0M
EPS (Diluted)	$-0.84 +71.5%	$-2.95 +17.4%	$-3.57	—	—	—
Total Assets	$95.9M +22.0%	$78.7M -24.9%	$104.7M +1912.8%	$5.2M -95.7%	$121.8M +15.4%	$105.5M
Total Debt	—	—	—	$14.5M -27.3%	$20.0M +0.0%	$20.0M
Operating Cash Flow	$-33.5M +20.5%	$-42.1M +0.2%	$-42.2M -85.9%	$-22.7M +55.9%	$-51.5M -17.6%	$-43.8M

AI Insight: LRMR Financial Trends

Larimar is a pre-revenue biotech burning cash at an accelerating rate, with equity depleted 25% in one year and no sign of clinical or commercial inflection.

• Operating losses widened from $25M (Q2 2024) to $64M (Q4 2025), then moderated to $31M (Q1 2026).

• Equity eroded from $211M (Q2 2024) to $78M (Q4 2025); slight recovery to $158M (Q1 2026) suggests financing activity.

• Operating cash burn averaged $23M per quarter across available data; no revenue generation visible.

⚠ Q4 2025 net loss spiked to $62M—largest quarterly loss on record—before moderation; driver unclear from financials alone.

⚠ Cash runway critical: at current burn rate (~$30M+ per quarter), equity base of $158M supports <6 quarters of operations.

AI Insight: LRMR Ratio Trends

Larimar remains deeply unprofitable with deteriorating returns; ROE swung from -137% in Q3 2025 to -75% in Q1 2026, signaling operational instability.

• ROE improved from -137.3% (Q3 2025) to -75.0% (Q1 2026), but remains severely negative; no path to profitability evident.

• ROA recovered from lowest point but remains deeply negative at -56.8% (Q1 2026), reflecting ongoing net losses and asset base erosion.

⚠ Extreme volatility in returns (ROE ranged -31% to -137% over 8 quarters) indicates execution inconsistency or accounting/timing swings.

⚠ No positive profitability or cash-generation metrics visible; stage-dependent biotech burning capital with no near-term inflection.

Get alerted when LRMR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Larimar Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LRMR

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$160.2M35,606,974 sh
Blue Owl Capital Holdings LP
$32.0M7,120,007 sh
BlackRock, Inc.
$16.9M3,752,200 sh
MILLENNIUM MANAGEMENT LLC
$16.3M3,625,278 sh
AIGH Capital Management LLC
$13.5M3,000,000 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$13.2M2,934,399 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.9M2,866,349 sh
DAFNA Capital Management LLC
$9.1M2,029,164 sh
GOLDMAN SACHS GROUP INC
$7.0M1,561,585 sh
Deep Track Capital, LP
$6.8M1,500,000 sh

Fund	Value	Shares
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$160.2M	35,606,974
Blue Owl Capital Holdings LP	$32.0M	7,120,007
BlackRock, Inc.	$16.9M	3,752,200
MILLENNIUM MANAGEMENT LLC	$16.3M	3,625,278
AIGH Capital Management LLC	$13.5M	3,000,000
DRIEHAUS CAPITAL MANAGEMENT LLC	$13.2M	2,934,399
VANGUARD CAPITAL MANAGEMENT LLC	$12.9M	2,866,349
DAFNA Capital Management LLC	$9.1M	2,029,164
GOLDMAN SACHS GROUP INC	$7.0M	1,561,585
Deep Track Capital, LP	$6.8M	1,500,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LRMR on your watchlist

Track score changes the day Larimar Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LRMR a good stock to buy?

13F Pro's AI-powered analysis of Larimar Therapeutics, Inc. (LRMR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LRMR are available on the LRMR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LRMR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LRMR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Larimar Therapeutics, Inc.'s investment landscape.